HA1 (ARHGAP45) Rabbit Polyclonal Antibody

CAT#: TA372703

ARHGAP45 rabbit polyclonal antibody

Product Images

Immunohistochemistry of paraffin-embedded Human breast cancer tissue using TA372703 (ARHGAP45 Antibody) at dilution 1/20 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human breast cancer tissue using TA372703 (ARHGAP45 Antibody) at dilution 1/20, treated with synthetic peptide. (Original magnification: ×200)

Specifications

Product Data

• Applications: IHC
• Recommended Dilution: IHC: 10-50
  Positive control: Human breast cancer
  Predicted cell location: Cytoplasm
• Reactivities: Human
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: Synthetic peptide of human ARHGAP45
• Formulation: pH7.4 PBS, 0.05% NaN3, 40% Glycerol
• Concentration: lot specific
• Purification: Antigen affinity purification
• Conjugation: Unconjugated
• Storage: Store at -20°C.
• Stability: 1 year
• Gene Name: histocompatibility (minor) HA-1
• Database Link:
  Entrez Gene 23526 Human
  UniProt ID Q92619
• Background: Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domin which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.
• Synonyms: HA-1; HLA-HA1; KIAA0223